Private Placement

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

Ashika Investment Managers launches a fund to capture India's next growth wave. Can its disciplined, data-driven strategy unlock value in a volatile market?

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

Advanced chip packaging is the unsung hero of the AI revolution, with a market set to explode. But can the industry sustain its billion-dollar habit?

As Thailand braces for another toxic smog season, air purifier giant Levoit deploys a timely strategy to capture a market born from a public health crisis.

A Japanese chemical plant's new AI-powered microgrid reveals how firms are using renewables not just for ESG, but as a defense against disaster and grid failure.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

The ADA’s new standards push for tech from day one and holistic care, but can the system deliver this innovative future to every patient?

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

After crossing $1B in assets, a community bank adds a healthcare PE expert to its board. This is more than a hire—it's a new strategy for growth.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New clinical data on VALTOCO nasal spray shows significant benefits for young children, reinforcing the critical need for rapid seizure intervention.